New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:25 EDTACAD, ACAD, ACAD, JAZZ, JAZZ, JAZZ, FRX, FRX, FRX, MDCO, MDCO, MDCO, SLXP, SLXP, SLXP, VRX, VRX, VRX, VRTX, VRTX, VRTX, SGMO, SGMO, SGMO, PCYC, PCYC, PCYC, PDLI, PDLI, PDLI, ISIS, ISIS, ISIS, HZNP, HZNP, HZNP, GILD, GILD, GILD, CELG, CELG, CELG, BIIB, BIIB, BIIB, BDSI, BDSI, BDSI, NKTR, NKTR, NKTRPiper Jaffray's technical analyst holds an analyst/industry conference call
Senior Technical Analyst Johnson provides an overview of the firm's covered universes, Biotech & Specialty Pharmaceuticals, from the viewpoint of a technical analyst on an Analyst/Industry conference call to be held on January 21 at 10 am.
News For ACAD;BDSI;BIIB;CELG;GILD;HZNP;ISIS;PDLI;PCYC;SGMO;VRTX;VRX;SLXP;MDCO;FRX;JAZZ;NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 13, 2015
06:47 EDTHZNPHorizon Pharma UCD treatment has upside potential, says Piper Jaffray
After surveying 16 physicians who treat patients with urea cycle disorders, Piper Jaffray sees "ample room" for further growth of Horizon Pharma's Ravicti. Piper believes its Ravicti estimates could prove conservative and reiterates an Overweight rating on Horizon with a $38 price target.
May 12, 2015
17:54 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:49 EDTVRTXVertex resumes after-hours trading, shares up 5.6% to $131.00
Subscribe for More Information
16:20 EDTVRTXVertex to resume trading at 14:45
16:19 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
Subscribe for More Information
16:16 EDTVRTXVertex confirms FDA panel voted 12-to-1 to recommend approval of Orkambi
16:16 EDTVRTXPiper Jaffray remains confident in approval for Vertex
Subscribe for More Information
15:43 EDTVRTXFDA panel votes 12 to 1 that data supports Orkambi approval
Subscribe for More Information
15:35 EDTVRTXFDA panel votes unanimously that data support Orkambi safety
Subscribe for More Information
15:32 EDTVRTXFDA panel inconclusive on if Lumacaftor contributes to Orkambi effectiveness
Subscribe for More Information
10:23 EDTVRTXVertex shares halted while FDA panel meeting takes place
10:16 EDTHZNPOptions with decreasing implied volatility
Options with decreasing implied volatility: NDLS WTW FUEL AOL LC NLNK ZU CYBR ARWR HZNP
07:58 EDTVRTXFDA Pulmonary-Allergy Drugs Advisory Committee to hold a meeting
Subscribe for More Information
07:33 EDTCELGAlliqua announces licensing agreement with Celgene
Subscribe for More Information
07:00 EDTBDSIBioDelivery Sciences price target lowered to $12 from $17 at Cantor
Subscribe for More Information
May 11, 2015
10:19 EDTHZNPFMR reports 11.4% passive stake in Horizon Pharma
Subscribe for More Information
10:17 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
07:40 EDTVRTXFocus on Vertex will shift to pricing after Orkambi FDA meeting, WSJ says
An FDA advisory committee that meets Tuesday to decide whether to recommend approval of Vertexís Orkambi will be closely watched by health insurers and pharmacy-benefit managers concerned that the experimental cystic-fibrosis drug will be high-priced, said The Wall Street Journal. Vertex hasnít announced a price, but analyst at JPMorgan predict the drug will have a wholesale price of about $287,000 annually per patient. Publicly traded PBM owners include Catamaran (CTRX), which is being acquired by UnitedHealth (UNH), CVS Health (CVS) and Express Scripts (ESRX). Reference Link
07:16 EDTBDSIBioDelivery Sciences reports 11K prescriptions dispensed for Bunavail during Q1
Subscribe for More Information
07:16 EDTBDSIBioDelivery Sciences reports Q1 EPS (16c), consensus (19c)
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use